2-[5-[[4-methyl-6-(4-methyl-1,3-benzoxazol-2-yl)-2-propylbenzimidazol-1-yl]methyl]indol-1-yl]benzoic acid
C35H30N4O3 — CID 155541169
Data last refreshed: (MolForge compound catalog, from PubChem)
About 2-[5-[[4-methyl-6-(4-methyl-1,3-benzoxazol-2-yl)-2-propylbenzimidazol-1-yl]methyl]indol-1-yl]benzoic acid
2-[5-[[4-methyl-6-(4-methyl-1,3-benzoxazol-2-yl)-2-propylbenzimidazol-1-yl]methyl]indol-1-yl]benzoic acid (PubChem CID 155541169) has the molecular formula C35H30N4O3 and a molecular weight of 554.65 g/mol. Its IUPAC name is 2-[5-[[4-methyl-6-(4-methyl-1,3-benzoxazol-2-yl)-2-propylbenzimidazol-1-yl]methyl]indol-1-yl]benzoic acid.
Molecular Properties
| Compound Name | 2-[5-[[4-methyl-6-(4-methyl-1,3-benzoxazol-2-yl)-2-propylbenzimidazol-1-yl]methyl]indol-1-yl]benzoic acid |
|---|---|
| PubChem CID | 155541169 |
| Molecular Formula | C35H30N4O3 |
| Molecular Weight | 554.65 g/mol |
| Exact Mass | 554.23 |
| IUPAC Name | 2-[5-[[4-methyl-6-(4-methyl-1,3-benzoxazol-2-yl)-2-propylbenzimidazol-1-yl]methyl]indol-1-yl]benzoic acid |
| SMILES | CCCc1nc2c(C)cc(-c3nc4c(C)cccc4o3)cc2n1Cc1ccc2c(ccn2-c2ccccc2C(=O)O)c1 |
| InChI | InChI=1S/C35H30N4O3/c1-4-8-31-36-32-22(3)17-25(34-37-33-21(2)9-7-12-30(33)42-34)19-29(32)39(31)20-23-13-14-27-24(18-23)15-16-38(27)28-11-6-5-10-26(28)35(40)41/h5-7,9-19H,4,8,20H2,1-3H3,(H,40,41) |
| InChIKey | HRXOSSBVMCILIE-UHFFFAOYSA-N |
| XLogP | 8.10 |
| TPSA | 86.08 Ų |
| H-Bond Donors | 1 |
| H-Bond Acceptors | 6 |
| Rotatable Bonds | 7 |
| Heavy Atoms | 42 |
| Complexity | — |
Lipinski Rule of Five
2 violations
| Rule | Value |
|---|---|
| MW ≤ 500 | 554.65 |
| LogP ≤ 5 | 8.10 |
| H-Bond Donors ≤ 5 | 1 |
| H-Bond Acceptors ≤ 10 | 6 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 155541169 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.